Modelos de Previsão de Desenvolvimento da COVID-19 em Doentes de Risco para uma Medicina de Precisão / Predictive Models of COVID-19 Outcomes for Higher Risk Patients Towards a Precision Medicine

Grant number: DSAIPA/DS/0117/2020

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    -99
  • Known Financial Commitments (USD)

    $0
  • Funder

    FCT Portugal
  • Principal Investigator

    Luís Filipe Nunes Bento
  • Research Location

    Portugal
  • Lead Research Institution

    Centro Hospitalar Universitário de Lisboa Central, EPE (CHULC)
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Publicationslinked via Europe PMC

Predicting delirium in critically Ill COVID-19 patients using EEG-derived data: a machine learning approach.

Analyzing Heart Rate Variability for COVID-19 ICU Mortality Prediction Using Continuous Signal Processing Techniques

Predicting ICU Delirium in Critically Ill COVID-19 Patients Using Demographic, Clinical, and Laboratory Admission Data: A Machine Learning Approach.

Cytokine-Based Insights into Bloodstream Infections and Bacterial Gram Typing in ICU COVID-19 Patients.

Early Mortality Prediction in Intensive Care Unit Patients Based on Serum Metabolomic Fingerprint.

Integration of FTIR Spectroscopy and Machine Learning for Kidney Allograft Rejection: A Complementary Diagnostic Tool.

Comparison of two metabolomics-platforms to discover biomarkers in critically ill patients from serum analysis.

Analysis of six consecutive waves of ICU-admitted COVID-19 patients: key findings and insights from a Portuguese population.

Bridging the gap between target-based and phenotypic-based drug discovery.